Browsing by Subject "Diffuse large B-cell lymphoma"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Novel Immune-Based treatments for Diffuse Large B-Cell Lymphoma: The Post-CAR T Cell Era
    (Frontiers Media, 2022-06-01) Atallah-Yunes, Suheil Albert; Robertson, Michael J.; Davé, Utpal P.; Ghione, Paola; Perna, Fabiana; Medicine, School of Medicine
    Prognosis for patients with refractory/relapsed (R/R) diffuse large B-cell lymphoma (DLBCL) is poor. Immune-based therapeutic treatments such as CD19 Chimeric Antigen Receptor (CAR) T cell therapies have dramatically changed the treatment landscape for R/R DLBCL leading to durable remissions in ~ 50% of patients. However, there remains an unmet need for developing novel therapies to improve clinical outcomes of patients not responding or relapsing after CAR T cell therapies. Lack of suitable immunotherapeutic targets and disease heterogeneity represent the foremost challenges in this emerging field. In this review, we discuss the recently approved and emerging novel immunotherapies for patients with R/R DLBCL in the post-CAR T era and the cell surface targets currently used.
  • Thumbnail Image
    Item
    Progression of follicular lymphoma and related entities: Report from the 2021 SH/EAHP Workshop
    (Oxford University Press, 2023-05-11) Duffield, Amy S.; Dogan, Ahmet; Amador, Catalina; Cook, James R.; Czader, Magdalena; Goodlad, John R.; Nejati, Reza; Xiao, Wenbin; Happ, Lanie; Parker, Clay; Thacker, Elizabeth; Thakkar, Devang; Dave, Sandeep S.; Wasik, Mariusz A.; Ott, German; Pathology and Laboratory Medicine, School of Medicine
    Objectives: The 2021 Society for Hematopathology and European Association for Haematopathology Workshop addressed the molecular and cytogenetic underpinnings of transformation and transdifferentiation in lymphoid neoplasms. Methods: Session 4, "Transformations of Follicular Lymphoma," and session 5, "Transformations of Other B-Cell Lymphomas," included 45 cases. Gene alteration analysis and expression profiling were performed on cases with submitted formalin-fixed, paraffin embedded tissue. Results: The findings from session 4 suggest that "diffuse large B-cell lymphoma/high-grade B-cell lymphoma with rearrangements of MYC and BCL2" is a distinct category arising from the constraints of a preexisting BCL2 translocation. TdT expression in aggressive B-cell lymphomas is associated with MYC rearrangements, immunophenotypic immaturity, and a dismal prognosis but must be differentiated from lymphoblastic -lymphoma. Cases in session 5 illustrated unusual morphologic and immunophenotypic patterns of transformation. Additionally, the findings support the role of cytogenetic abnormalities-specifically, MYC and NOTCH1 rearrangements-as well as single gene alterations, including TP53, in transformation. Conclusions: Together, these unique cases and their accompanying molecular and cytogenetic data suggest potential mechanisms for and unusual patterns of transformation in B-cell lymphomas and indicate numerous opportunities for further study.